Known targets — ChEMBL curated mechanism
FAURPL10RPL10ARPL11RPL12RPL13RPL13ARPL14RPL15RPL17RPL18RPL18ARPL19RPL21RPL22RPL23RPL23ARPL24RPL26RPL27RPL27ARPL28RPL29RPL3RPL30RPL31RPL32RPL34RPL35RPL35ARPL36RPL36ARPL37RPL37ARPL38RPL39RPL4RPL41RPL5RPL6RPL7RPL7ARPL8RPL9RPL9P7RPL9P8RPL9P9RPLP0RPLP1RPS10RPS11RPS12RPS13RPS14RPS15RPS15ARPS16RPS17RPS18RPS19RPS2RPS20RPS21RPS23RPS24RPS25RPS26RPS27RPS27ARPS28RPS29RPS3RPS3ARPS4XRPS4Y1RPS5RPS6RPS7RPS8RPS9RPSA
The experimentally established mechanism targets of Ataluren. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAOA | P21397 | 1/20 | 0.97 |
| ▸ | BLVRB | P30043 | 1/20 | 0.97 |
| ▸ | HDAC6 | Q9UBN7 | 1/20 | 0.97 |
| ▸ | NPC1 | O15118 | 13/20 | 0.77 |
| ▸ | RAB9A | P51151 | 13/20 | 0.77 |
| ▸ | KMT2A | Q03164 | 5/20 | 0.68 |
| ▸ | SMN1; SMN2 | Q16637 | 5/20 | 0.68 |
| ▸ | MEN1 | O00255 | 4/20 | 0.68 |
| ▸ | L3MBTL1 | Q9Y468 | 3/20 | 0.68 |
| ▸ | NFKB1 | P19838 | 3/20 | 0.68 |
| ▸ | NFKB2 | Q00653 | 3/20 | 0.68 |
| ▸ | RELA | Q04206 | 3/20 | 0.68 |
| ▸ | PKM | P14618 | 2/20 | 0.68 |
| ▸ | MAPK1 | P28482 | 2/20 | 0.68 |
| ▸ | NR1H4 | Q96RI1 | 1/20 | 0.60 |
| ▸ | MAPT | P10636 | 2/20 | 0.51 |
| ▸ | TP53 | P04637 | 1/20 | 0.51 |
| ▸ | GAA | P10253 | 1/20 | 0.50 |
| ▸ | CHUK | O15111 | 1/20 | 0.49 |
| ▸ | CASP3 | P42574 | 1/20 | 0.49 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Ataluren SCHEMBL29360108 | 0.99 | MAOA (1.00) | MAOABLVRBHDAC6NPC1RAB9A | |
| Ataluren SCHEMBL29365205 | 0.99 | MAOA (1.00) | MAOABLVRBHDAC6NPC1RAB9A | |
| Ataluren SCHEMBL60614 | 0.99 | MAOA (1.00) | MAOABLVRBHDAC6NPC1RAB9A | |
| Ataluren SCHEMBL29361641 | 0.99 | MAOA (1.00) | MAOABLVRBHDAC6NPC1RAB9A | |
| Ataluren SCHEMBL59167 | 0.97 | MAOA (0.97) | MAOABLVRBHDAC6NPC1RAB9A | |
| SCHEMBL60044 | 0.90 | MAOA (0.83) | MAOABLVRBHDAC6NPC1RAB9A | |
| SCHEMBL1505230 | 0.88 | MAOA (0.81) | MAOABLVRBHDAC6NPC1RAB9A | |
| SCHEMBL60083 | 0.88 | HDAC6 (0.80) | MAOABLVRBHDAC6NPC1RAB9A | |
| SCHEMBL1752479 | 0.87 | NPC1 (1.00) | MAOABLVRBHDAC6NPC1RAB9A | |
| SCHEMBL17946207 | 0.87 | MAOA (0.79) | MAOABLVRBHDAC6NPC1RAB9A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 74 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9205088-B2 | Compositions of 1,2,4-oxadiazol benzoic acid compounds and methods for their use | PTC THERAPEUTICS, INC. (US) | 2015-12-08 | — | — | US | claimed |
| US-20150148346-A1 | COMPOSITIONS OF 1,2,4-OXADIAZOLE BENZOIC ACID COMPOUNDS AND METHODS FOR THEIR USE | PTC THERAPEUTICS INC. (US) | 2015-05-28 | — | — | US | claimed |
| US-8975287-B2 | Methods for using 1,2,4-Oxadiazole benzoic acid compounds | PTC THERAPEUTICS, INC. (US) | 2015-03-10 | — | — | US | claimed |
| EP-1618098-B1 | 1,2,4-OXADIAZOLE BENZOIC ACID COMPOUNDS AND THEIR USE FOR NONSENSE SUPPRESSION AND THE TREATMENT OF DISEASE | PTC THERAPEUTICS INC (US) | 2014-11-19 | — | — | EP | claimed |
| US-20140301978-A1 | METHODS FOR USING 1,2,4-OXADIAZOLE BENZOIC ACID COMPOUNDS | PTC THERAPEUTICS INC. (US) | 2014-10-09 | — | — | US | claimed |
| US-8486982-B2 | 1,2,4-oxadiazole benzoic acids | PTC THERAPEUTICS, INC. (US) | 2013-07-16 | — | — | US | claimed |
| US-20120277234-A1 | 1,2,4-OXADIAZOLE BENZOIC ACIDS | PTC THERAPEUTICS, INC. | 2012-11-01 | — | — | US | claimed |
| US-8299105-B2 | 1,2,4-oxadiazole benzoic acid compositions and their use in bioassays | PTC THERAPEUTICS, INC. (US) | 2012-10-30 | — | — | US | claimed |
| US-8227494-B2 | Pharmaceutical compositions of 1,2,4-oxadiazole benzoic acid and their use for the treatment of disease | PTC THERAPEUTICS, INC. (US) | 2012-07-24 | — | — | US | claimed |
| US-20120178080-A1 | 1,2,4-OXADIAZOLE BENZOIC ACID COMPOSITIONS AND THEIR USE IN BIOASSAYS | PTC THERAPEUTICS, INC. | 2012-07-12 | — | — | US | claimed |
| US-20100216851-A1 | 1,2,4-OXADIAZOLE BENZOIC ACID COMPOSITIONS AND THEIR USE IN BIOASSAYS | PTC THERAPEUTICS, INC. | 2010-08-26 | — | — | US | claimed |
| US-20100168109-A1 | PHARMACEUTICAL COMPOSITIONS OF 1,2,4-OXADIAZOLE BENZOIC ACID AND THEIR USE FOR THE TREATMENT OF DISEASE | PTC THERAPEUTICS, INC. | 2010-07-01 | — | — | US | claimed |
| US-7683082-B2 | 3-(5-p-tolyl-[1,2,4]oxadiazol-3-yl)-benzoic acid; translation of mRNA is allowed to continue past a nonsense mutation point, resulting in full length protein; genetic disorders; testing whether a compound increases activity of a protein encoded by an mRNA that contains a premature stop codon | PTC THERAPEUTICS, INC. (US) | 2010-03-23 | — | — | US | claimed |
| EP-1618098-A4 | 1,2,4-OXADIAZOLE BENZOIC ACID COMPOUNDS AND THEIR USE FOR NONSENSE SUPPRESSION AND THE TREATMENT OF DISEASE | PCT THERAPEUTICS INC (US) | 2008-07-16 | — | — | EP | claimed |
| US-20070161687-A1 | 3-(5-p-tolyl-[1,2,4]oxadiazol-3-yl)-benzoic acid; translation of mRNA is allowed to continue past a nonsense mutation point, resulting in full length protein; genetic disorders; testing whether a compound increases activity of a protein encoded by an mRNA that contains a premature stop codon | PTC THERAPEUTICS, INC. | 2007-07-12 | — | — | US | claimed |
| US-7202262-B2 | E.g., 3-(5-p-tolyl-[1,2,4]oxadiazol-3-yl)-benzoic acid; translation of mRNA is allowed to continue past a nonsense mutation point, resulting in the production of a full length protein; genetic disorders | PTC THERAPEUTICS, INC. (US) | 2007-04-10 | — | — | US | claimed |
| US-6992096-B2 | translation of mRNA is allowed to continue past a nonsense mutation point, resulting in the production of a full length protein; genetic disorders; 3-(5-p-tolyl-[1,2,4]oxadiazol-3-yl)-benzoic acid | PTC THERAPEUTICS, INC. (US) | 2006-01-31 | — | — | US | claimed |
| EP-1618098-A2 | 1,2,4-OXADIAZOLE BENZOIC ACID COMPOUNDS AND THEIR USE FOR NONSENSE SUPPRESSION AND THE TREATMENT OF DISEASE | PCT Therapeutics Inc. (US) | 2006-01-25 | — | — | EP | claimed |
| WO-2004091502-A2 | 1,2,4-OXADIAZOLE BENZOIC ACID COMPOUNDS | PTC THERAPEUTICS, INC. (US) | 2004-10-28 | — | — | WO | claimed |
| US-20040204461-A1 | translation of mRNA is allowed to continue past a nonsense mutation point, resulting in the production of a full length protein; genetic disorders; 3-(5-p-tolyl-[1,2,4]oxadiazol-3-yl)-benzoic acid | PTC THERAPEUTICS, INC. | 2004-10-14 | — | — | US | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120277234-A1 | 1,2,4-OXADIAZOLE BENZOIC ACIDS | UPF1, RIOX2, RPL35A | MAOA 3038/4885BLVRB 3244/4885HDAC6 479/4885 |
| US-20100168109-A1 | PHARMACEUTICAL COMPOSITIONS OF 1,2,4-OXADIAZOLE BENZOIC ACID AND THEIR USE FOR THE TREATMENT OF DISEASE | UPF1, RIOX2, PABPC1 | MAOA 2899/4885BLVRB 3556/4885HDAC6 302/4885 |
| US-20140301978-A1 | METHODS FOR USING 1,2,4-OXADIAZOLE BENZOIC ACID COMPOUNDS | UPF1, RIOX2, RNMT | MAOA 2113/4885BLVRB 2503/4885HDAC6 331/4885 |
| US-20150148346-A1 | COMPOSITIONS OF 1,2,4-OXADIAZOLE BENZOIC ACID COMPOUNDS AND METHODS FOR THEIR USE | UPF1, RIOX2, RNMT | MAOA 2168/4885BLVRB 2958/4885HDAC6 346/4885 |
| US-20100216851-A1 | 1,2,4-OXADIAZOLE BENZOIC ACID COMPOSITIONS AND THEIR USE IN BIOASSAYS | UPF1, RIOX2, RNGTT | MAOA 2457/4885BLVRB 2869/4885HDAC6 897/4885 |
| US-20070161687-A1 | 3-(5-p-tolyl-[1,2,4]oxadiazol-3-yl)-benzoic acid; translation of mRNA is allowed to continue past a nonsense mutation point, resulting in full length protein; genetic disorders; testing whether a compound increases activity of a protein encoded by an mRNA that contains a premature stop codon | UPF1, PABPC4, PABPC1 | MAOA 3625/4885BLVRB 2775/4885HDAC6 2378/4885 |
| US-20040204461-A1 | translation of mRNA is allowed to continue past a nonsense mutation point, resulting in the production of a full length protein; genetic disorders; 3-(5-p-tolyl-[1,2,4]oxadiazol-3-yl)-benzoic acid | UPF1, PABPC1, PABPC4 | MAOA 3758/4885BLVRB 3084/4885HDAC6 1524/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.